Cargando…

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

SIMPLE SUMMARY: Basal cell carcinoma is the most common skin cancer and new treatments for patients with widespread and numerous tumors are lacking. In a previous study treating patients with multiple myeloma with a peptide vaccine called IO103 against an immune checkpoint molecule called programmed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jørgensen, Nicolai Grønne, Kaae, Jeanette, Grauslund, Jacob Handlos, Met, Özcan, Nielsen, Signe Ledou, Pedersen, Ayako Wakatsuki, Svane, Inge Marie, Ehrnrooth, Eva, Andersen, Mads Hald, Zachariae, Claus, Skov, Lone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926323/ https://www.ncbi.nlm.nih.gov/pubmed/33671555 http://dx.doi.org/10.3390/cancers13040911

Ejemplares similares

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Novel immune modulatory vaccines targeting TGFβ
por: Andersen, Mads Hald
Publicado: (2023)

Side effects after artificial hair implants: 2 case reports
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report
por: Haulrig, Morten Bahrt, et al.
Publicado: (2022)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Persistent Cutaneous Papules and Nodules in a Six-year-old Child: A Quiz
por: HAUGAARD, Jeanette Halskou, et al.
Publicado: (2022)

Therapeutic Cancer Vaccines in Combination with Conventional Therapy
por: Andersen, Mads Hald, et al.
Publicado: (2010)

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022)

The targeting of tumor-associated macrophages by vaccination
por: Andersen, Mads Hald
Publicado: (2019)

Cancer treatment: the combination of vaccination with other therapies
por: Andersen, Mads Hald, et al.
Publicado: (2008)

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study
por: TODBERG, Tanja, et al.
Publicado: (2020)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
por: Perez-Penco, Maria, et al.
Publicado: (2022)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
por: Haulrig, Morten B, et al.
Publicado: (2021)

103. Evaluating The Appropriateness of Vaccine Administration in Patients with Splenectomy
por: Barsoum, Barbara, et al.
Publicado: (2022)

Successful Treatment of Posttransplant EBV-Associated Lymphoma and Plasmacytoma Solely Localized to the CNS
por: Hansen, Per Boye, et al.
Publicado: (2012)

A Potential Role of Indoleamine 2,3-Dioxygenase–Specific T cells in Leishmania Vaccination
por: Straten, Per thor, et al.
Publicado: (2011)

CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment
por: Lecoq, Inés, et al.
Publicado: (2022)

Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study
por: TODBERG, Tanja, et al.
Publicado: (2020)

Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels
por: SCHWARZ, Christopher Willy, et al.
Publicado: (2020)

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2018)

Effect of Marriage and Spousal Criminality on Recidivism
por: Andersen, Signe Hald, et al.
Publicado: (2015)

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
por: Andersen, Mads Hald, et al.
Publicado: (2006)

Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes
por: Køllgaard, Tania, et al.
Publicado: (2015)

Cohort profile: the clinical ‘Psoriasis in Adolescents’ (PIA) cohort in Denmark
por: Blegvad, Christoffer, et al.
Publicado: (2019)

Annular elastolytic giant cell granuloma in a patient with squamous cell carcinoma of the tonsil
por: Gyldenløve, Mette, et al.
Publicado: (2014)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review
por: TODBERG, Tanja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8mco7b6kkl39l78f74pj0qqdv7